R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Manager - Regional Access

Growth & MarketingConfirmed live in the last 24 hours
Full-timeMunich, GermanyNo salary listedRemote

About the Job

Requirements

  • A bachelor's degree is required.
  • At least 6 years of experience in a Regional Market Access role within the pharmaceutical or biopharma industry is required.
  • Extensive experience working with statutory health insurance companies in Germany, physicians’ associations, MDK (Medizinischer Dienst), and other stakeholders is required.
  • Extensive knowledge of regulations in the German pharmaceutical healthcare system is required, including the legal pricing framework, post-AMNOG system-imminent access hurdles, dispensing of pharmaceuticals, taxation and reimbursement, (re-)importation of pharmaceuticals, patient-individual importation of drugs, and federal or regional contracts on dispensing pharmaceuticals such as dispensing quotas and Praxisbesonderheiten.
  • Successful interaction with relevant stakeholders within Germany’s self-governing bodies is required.

Responsibilities

  • Drive execution of regional and local market access priorities within the national market access strategy, identifying and prioritizing barriers to timely and sustainable patient access.
  • Provide hands-on support for key launch activities across Germany and support country-level regional and local market access tactics and initiatives to secure reimbursement of the company’s assets.
  • Work with sales, marketing, government affairs, and medical departments to develop and execute market access solutions aligned with the commercial business strategy, engaging internal and external stakeholders including hospitals, office-based oncologists, pharmacies, health insurers, medical associations, and policymakers.
  • Secure listing of the company’s assets in hospital pharmacy lists once available across Germany and identify organizational hurdles that could hinder broad adoption in existing treatment algorithms.
  • Identify market-specific needs of prescribers, pharmaceutical decision makers, and health policy stakeholders, and develop tactics to address evolving market access barriers.
  • Identify access barriers and develop or recommend regional or local approaches and tactics within the established market-access strategy to enable patient access. This may include named-patient access when needed, in compliance with relevant regulations for industry involvement.
  • Establish and maintain a network among opinion leaders, health insurers, physicians’ associations, and health policymakers.
  • Serve as a primary contact point for market access stakeholder groups, including health insurers (including MDK), pharmacies, and hospital administrators.
  • Monitor, collect, and share insights on emerging pharmaceutical policy, pricing, and market access reimbursement framework changes relevant to the company’s assets; translate regional insights into actionable recommendations for regional and national market access teams to inform launch and lifecycle planning.
  • Represent the company and its assets to relevant healthcare bodies and stakeholders in Germany.
  • With the Regional Access team, initiate and organize regional or local events and projects to support reimbursement activities; provide internal and external explanations and training materials on market access topics for relevant stakeholder groups.
  • Partner with Sales, Medical, and other relevant functions to address regional patient-access barriers, take ownership of agreed access-related initiatives, and provide reimbursement expertise, including supporting arguments about the innovative value of the company’s assets, participating in reimbursement and market access discussions with German oncologists, and supporting NUB applications for hospital use of the assets in Germany.

Desired Qualifications

  • An advanced degree in Pharmacy, Health Economics, Public Health, Life Sciences, or Business is preferred, for example PharmD, PhD, or MBA.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs